Liver Disease
Conference Coverage
What is new in hepatology in 2023?
There has been a paradigm shift in risk stratification of cirrhosis and targets for prevention and treatment of decompensation.
News from the FDA/CDC
FDA advisory committee votes against approval for NASH drug
“Typically, in clinical practice, NASH patients are followed every 6-12 months, so more frequent monitoring would be a substantial change and may...
Conference Coverage
Analysis: 40% of information about cirrhosis on TikTok is incorrect
Study presented at DDW finds that patient-derived sources are usually trustworthy, promotional sources are often misleading.
Latest News
Harnessing ChatGPT to improve liver disease outcomes
ChatGPT information is correct, but inadequate.
Latest News
Dried blood spot test validated for HIV, hep B, and hep C
“This method is particularly useful in high-risk settings such as homeless shelters, drug rehabilitation centers, and prisons, where ... it can be...
From the Journals
Racial disparities not found in chronic hepatitis B treatment initiation
Treatment guidelines need to be simplified and that efforts to increase hepatitis B virus (HBV) awareness and train more clinicians are needed.
From the AGA Journals
Refined incidence rate of HCC with alcohol-associated cirrhosis encourages surveillance
Cumulative risk of HCC in patients with alcohol-associated cirrhosis was 3% after 5 years, and 9% after 10 years.
From the AGA Journals
Antibiotic pretreatment reduces liver ischemia/reperfusion injury
Therapies that target macrophage metabolism could serve as potential treatment options.
From the Journals
No added benefit of time-restricted eating in NAFLD
8-hour time-restricted eating was no more effective in lowering IHTG and resolving NAFLD than daily calorie restriction.
From the Journals
Semaglutide doesn’t improve fibrosis in NASH-related cirrhosis
However, semaglutide was successful in improving other clinically important parameters.